Previous 10 | Next 10 |
2023-11-14 16:28:03 ET Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Conference Call November 14, 2023 08:00 AM ET Company Participants Robert Shawah - CFO David Luci - President & CEO Robert DeLuccia - Executive Chairman Conference Call Participa...
2023-11-14 07:23:11 ET More on Acurx Pharmaceuticals Acurx Undervalued And Set For Potential M&A With Next-Gen C. Diff Treatment Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Acurx Pharma falls after mid-stage data for lead asset ...
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Nov. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical c...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Acurx Pharmaceuticals Inc. (ACXP) is expected to report $-0.28 for Q3 2023
2023-11-06 10:01:49 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
2023-11-06 09:00:00 ET Summary Acurx is a promising antibiotic company with perfect Phase 2a data in treating C. difficile infection. The company is developing a novel antibiotic, ibezapolstat, which could be the first new class of antibiotics in decades. Ibezapolstat has show...
2023-11-06 08:17:52 ET Losers: MoonLake Immunotherapeutics ( MLTX ) -30% . Tecnoglass ( TGLS ) -15% after Q3 earning release . Kodiak Sciences ( KOD ) -11% says Phase 3 trial for lead asset met key goals. Arrival ( ARVL ) -9% . A...
2023-11-03 08:22:27 ET More on pre-market losers stock Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Acurx Pharma falls after mid-stage data for lead asset AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio ...
2023-11-02 14:10:27 ET More on Acurx Pharma Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Acurx Pharmaceuticals, Inc. (ACXP) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals Historical...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...